Comment from Center on Reproductive Health, Law, and Policy

Summary: The UCLA Law Center for Reproductive Health, Law, and Policy and UCSF Advancing New Standards in Reproductive Health, representing 263 reproductive health researchers, submit this comment in support of petitions asking the FDA to refrain from imposing additional restrictions on mifepristone. They argue that decades of gold-standard science confirm the safety and effectiveness of mifepristone, including via telehealth, and criticize recent reports by the Ethics and Public Policy Center as methodologically flawed and non-reproducible.